Long-term follow-up of mesh-covered stent implantation in patients with ST-segment elevation myocardial infarction

Kardiologia Polska

Volumn 72, Issue 2, 2014, Pages 140-145

  Dudek, Dariusz ^a   Dziewierz, Artur ^a   Kleczyński, Paweł ^a   Giszterowicz, Dawid ^b   Rakowski, Tomasz ^a   Sorysz, Danuta ^a   Rzeszutko, Łukasz ^a   Legutko, Jacek ^a   Bartuś, Stanislaw ^a   Dragan, Jacek ^b   Klecha, Artur ^b   Siudak, Zbigniew ^a   Zmudka, Krzysztof ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Department of Interventional Cardiology ^*  (Poland)

Author keywords

Acute myocardial infarction; Long term outcomes; Mesh; Primary angioplasty; Stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PREMEDICATION; PROSPECTIVE STUDY; SAFETY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT OUTCOME; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; EMBOLIC PROTECTION DEVICE; LONG TERM ADVERSE EFFECTS; MIDDLE AGED; MYOCARDIAL INFARCTION; STENT; SURGICAL MESH; TIME FACTOR;

AGED; EMBOLIC PROTECTION DEVICES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG TERM ADVERSE EFFECTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; STENTS; SURGICAL MESH; TIME FACTORS;

EID: 84895096700     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.a2013.0252     Document Type: Article

References (17)

1. Kaluski E, Tsai S, Klapholz M. Coronary stenting with MGuard: from conception to human trials. Cardiovasc Revasc Med, 2008; 9: 88-94.
2. Dziewierz A, Dudek D. Advantages of MGuard coronary stent system. Minerva Cardioangiol, 2012; 60: 33-40.
3. Kaluski E, Hauptmann KE, Muller R et al. Coronary stenting with MGuard: first-in-man trial. J Invasive Cardiol, 2008; 20: 511-515.
4. Dudek D, Dziewierz A, Rzeszutko L et al. Mesh covered stent in ST-segment elevation myocardial infarction. EuroIntervention, 2010; 6: 582-589.
5. Piscione F, Danzi GB, Cassese S et al. Multicentre experience with MGuard net protective stent in ST-elevation myocardial infarction: safety, feasibility, and impact on myocardial reperfusion. Catheter Cardiovasc Interv, 2010; 75: 715-721.
6. Stone GW, Abizaid A, Silber S et al. Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-segment elevation myocardial infarction: the MASTER Trial. J Am Coll Cardiol, 2012; 60: 1975-1984.
7. Cutlip DE, Windecker S, Mehran R et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 2007; 115: 2344-2351.
8. Stone GW, Peterson MA, Lansky AJ et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol, 2002; 39: 591-597.
9. Henriques JP, Zijlstra F, van't Hof AW et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation, 2003; 107: 2115-2119.
10. Fokkema ML, Vlaar PJ, Svilaas T et al. Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction. Eur Heart J, 2009; 30: 908-915.
11. Grube E, Hauptmann KE, Muller R et al. Coronary stenting with MGuard: extended follow-up of first human trial. Cardiovasc Revasc Med, 2011; 12: 138-146.
12. Stone GW, Witzenbichler B, Guagliumi G et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet, 2011; 377: 2193-2204.
13. Campo G, Saia F, Percoco G, et al. Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry. Int J Cardiol, 2010; 140: 154-160.
14. Dziewierz A, Siudak Z, Rakowski T et al. Drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER Registry. Clin Res Cardiol, 2011; 100: 139-145.
15. Kübler P, Jankowska EA, Ferenc M et al. Comparison of drug-eluting stents to bare-metal stents in ST-elevation myocardial infarction in long-term follow-up. Kardiol Pol, 2013; 71: 25-31.
16. Stone GW, Parise H, Witzenbichler B et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS- AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol, 2010; 56: 1597-1604.
17. Cassese S, Esposito G, Mauro C et al. MGUard versus bAre-metal stents plus manual thRombectomy in ST-elevation myocardial infarction pAtieNts-(GUARDIAN) trial: study design and rationale. Catheter Cardiovasc Interv, 2012; 79: 1118-1126.